Annals of Oncology 14:291-297, 2003
© 2003 European Society for Medical Oncology
Original Paper |
A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
1 Institut Multidisciplinaire d’Oncologie, Clinique de Genolier, Vaud; 2 Department of Medicine C, Kantonsspital, Sankt Gallen; 3 Istituto Oncologico Cantonale, Ospedale San Giovanni, Bellinzona; 4 Division d’Oncologie, Hôpital Cantonal Universitaire, Genève; 5 Swiss Institute for Applied Cancer Research Coordinating Centre, Bern, Switzerland
Received 4 March 2002; revised 20 September 2002; accepted 22 October 2002
Background:
The prophylactic use of 5-HT3 receptor antagonists (setrons), after the first 24 h (acute phase) of exposure to emetic chemotherapy, to decrease the incidence of ‘delayed phase’ emesis increases costs. We designed a study to evaluate the efficacy of a setron (granisetron) in the delayed phase, compared with metoclopramide, each combined with a corticosteroid.
Patients and methods:
Patients on their first course of single-day emetic chemotherapy (cisplatin, carboplatin, doxorubicin, cyclophosphamide and others) received granisetron 2 mg p.o. and dexamethasone 8 mg p.o. on day 1, followed for 5 days by dexamethasone 4 mg p.o. od combined with either metoclopramide 20 mg p.o. tds or granisetron 1 mg bd in a double-blinded double-dummy protocol. Patients evaluated the results using a diary card. Randomization was stratified by institution, sex, emetic chemotherapy naïve versus previous, alcohol consumption and platinum versus non-platinum regimen.
Results:
131 evaluable patients received granisetron in the delayed phase, and 127 received metoclopramide. Control of acute emesis in both arms was similar (86% granisetron; 85% metoclopramide). The 35 patients experiencing acute emesis had poor control in the delayed phase, with only four granisetron and three metoclopramide patients having no or mild nausea and no vomiting.
Conclusions:
In daily practice, a combination of oral dexamethasone and oral granisetron achieves an extremely high control of acute emesis (86% protection). Our data suggest that routine prescription of setrons for delayed phase control is not advisable as it increases costs without any benefit for the majority of patients. Delayed emesis in the rare patients with acute phase emesis remains an unsolved problem.
Key words: acute, delayed, dexamethasone, granisetron, nausea, vomiting
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Yonemura, N. Katsumata, H. Hashimoto, S. Satake, M. Kaneko, Y. Kobayashi, A. Takashima, Y. Kato, M. Takeuchi, Y. Fujiwara, et al. Randomized Controlled Study Comparing Two Doses of Intravenous Granisetron (1 and 3 mg) for Acute Chemotherapy-induced Nausea and Vomiting in Cancer Patients: A Non-inferiority Trial Jpn. J. Clin. Oncol., July 1, 2009; 39(7): 443 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chan, V. Shih, and L. Chew Evolving roles of oncology pharmacists in Singapore: A survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre{dagger} Journal of Oncology Pharmacy Practice, March 1, 2008; 14(1): 23 - 29. [Abstract] [PDF]
|
|
|
|
 |
|
 M. T Holdsworth and T. Vo-Nguyen Employment of Substandard Antiemetic Prophylaxis in Recent Trials of Chemotherapy-Induced Nausea and Vomiting Ann. Pharmacother., November 1, 2005; 39(11): 1903 - 1910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Aapro Granisetron: An Update on its Clinical Use in the Management of Nausea and Vomiting Oncologist, November 1, 2004; 9(6): 673 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Eisenberg, F. R. MacKintosh, P. Ritch, P. A. Cornett, and A. Macciocchi Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study Ann. Onc., February 1, 2004; 15(2): 330 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gralla, M. Lichinitser, S. Van der Vegt, H. Sleeboom, J. Mezger, C. Peschel, G. Tonini, R. Labianca, A. Macciocchi, and M. Aapro Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann. Onc., October 1, 2003; 14(10): 1570 - 1577. [Abstract] [Full Text] [PDF]
|
|